Company Encyclopedia
View More
name
Astrazeneca
AZN.US
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases.
4.359 T
AZN.USMarket value -Rank by Market Cap -/-

Financial Score

14/11/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking4/180
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE21.70%A
    • Profit Margin16.17%A
    • Gross Margin81.62%A
  • Growth ScoreB
    • Revenue YoY13.52%B
    • Net Profit YoY44.71%B
    • Total Assets YoY9.09%B
    • Net Assets YoY12.66%B
  • Cash ScoreB
    • Cash Flow Margin618.44%C
    • OCF YoY13.52%B
  • Operating ScoreC
    • Turnover0.53C
  • Debt ScoreD
    • Gearing Ratio59.84%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    European stocks "Eleven Arhats" closing report | On Friday, SAP fell 3.2%, while this week Novo Nordisk AS, Sanofi, Roche, LVMH Group, and Astrazeneca rose at least about 5%

    On November 14th, European stocks closed with SAP down 3.21% and Novo Nordisk down 2.39%, but up 6.82% for the week. GlaxoSmithKline, Novartis, Nestlé, Sanofi, Roche Holding, ASML Holding, L'Oréal, LVMH Group, and AstraZeneca all saw varying degrees of increase this week, with LVMH Group and AstraZeneca rising more than 5%

    Wallstreetcn·
    US
    RHHBY
    -1.25%
    US
    NVO
    -1.83%
    US
    AZN
    +0.55%
    Wallstreetcn·
    US
    RHHBY
    -1.25%
    US
    NVO
    -1.83%
    US
    AZN
    +0.55%

    AstraZeneca PLC $AZN Shares Sold by Nwam LLC

    Nwam LLC reduced its holdings in AstraZeneca PLC by 40.1% in Q2, now owning 7,036 shares valued at $535,000. Other institutional investors adjusted their positions, with some increasing their holdings. Analysts have mixed ratings, with a consensus of 'Moderate Buy' and a target price of $86. AstraZeneca's recent earnings beat expectations, with a revenue increase of 12% year-over-year.

    Market Beat·
    UK
    AZN
    0.00%
    US
    AZN
    +0.55%
    Market Beat·
    UK
    AZN
    0.00%
    US
    AZN
    +0.55%

    Bernstein Remains a Buy on AstraZeneca (AZN)

    Bernstein Remains a Buy on AstraZeneca (AZN)

    Tip Ranks·
    UK
    AZN
    0.00%
    US
    AZN
    +0.55%
    Tip Ranks·
    UK
    AZN
    0.00%
    US
    AZN
    +0.55%

    AstraZeneca PLC ADR Outperforms Competitors On Strong Trading Day

    AstraZeneca PLC ADR rose 1.06% to $88.61, outperforming competitors in a grim trading session where NASDAQ fell 2.29% and Dow Jones fell 1.65%. It closed 0.79% below its 52-week high. Competitors Eli Lilly, Biogen, and Johnson & Johnson also saw gains. Trading volume was below average. Data compiled on November 13, 2025.

    Dow Jones·
    US
    AZN
    +0.55%
    Dow Jones·
    US
    AZN
    +0.55%

    Health Rounds: Lilly blood thinner tops AstraZeneca's for heart procedure patients with diabetes

    A study from India found that Eli Lilly's Effient (prasugrel) is more effective than AstraZeneca's Brilinta (ticagrelor) for diabetes patients after heart procedures. The trial showed a lower combined rate of heart attack, stroke, bleeding complications, or death with prasugrel. Additionally, general anesthesia is deemed safe for C-sections when regional anesthesia is ineffective, according to a separate analysis.

    Reuters·
    US
    LLY
    +0.38%
    US
    AZN
    +0.55%
    Reuters·
    US
    LLY
    +0.38%
    US
    AZN
    +0.55%
    Posts
    View More

    The Nasdaq Composite Index fell 2.7%, with a cumulative annual decline of 10.3%. - The S&P 500 Index dropped 1.97%, with a cumulative annual decline of 5.1%. - The Dow Jones Index declined 1.69%, with...